|
1
|
Lehmann BD and Pietenpol JA:
Identification and use of biomarkers in treatment strategies for
triple-negative breast cancer subtypes. J Pathol. 232:142–150.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bosch A, Eroles P, Zaragoza R, Viña JR and
Lluch A: Triple-negative breast cancer: Molecular features,
pathogenesis, treatment and current lines of research. Cancer Treat
Rev. 36:206–215. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bae YH, Ryu JH, Park HJ, Kim KR, et al:
Mutant p53-Notch1 signaling axis is involved in curcumin-induced
apoptosis of breast cancer cells. Korean J Physiol Pharmacol.
17:291–297. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xu Y, Diao L, Chen Y, Liu Y, Wang C,
Ouyang T, Li J, Wang T, Fan Z, Fan T, et al: Promoter methylation
of BRCA1 in triple-negative breast cancer predicts sensitivity to
adjuvant chemotherapy. Ann Oncol. 24:1498–1505. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hudis CA and Gianni L: Triple-negative
breast cancer: An unmet medical need. Oncologist. 16(Suppl 1):
1–11. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jerónimo C, Costa I, Martins MC, Monteiro
P, Lisboa S, Palmeira C, Henrique R, Teixeira MR and Lopes C:
Detection of gene promoter hypermethylation in fine needle washings
from breast lesions. Clin Cancer Res. 9:3413–3417. 2003.PubMed/NCBI
|
|
7
|
Zhou L, Li K, Luo Y, Tian L, Wang M, Li C
and Huang Q: Novel prognostic markers for patients with
triple-negative breast cancer. Hum Pathol. 44:2180–2187. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ismail-Khan R and Bui MM: A review of
triple-negative breast cancer. Cancer Control. 17:173–176.
2010.PubMed/NCBI
|
|
9
|
Shitara K, Yamada H, Watanabe K, Shimonaka
M and Yamaguchi Y: Brain-specific receptor-type protein-tyrosine
phosphatase RPTP beta is a chondroitin sulfate proteoglycan in
vivo. J Biol Chem. 269:20189–20193. 1994.PubMed/NCBI
|
|
10
|
Jäger R, List B, Knabbe C, Souttou B,
Raulais D, Zeiler T, Wellstein A, Aigner A, Neubauer A and Zugmaier
G: Serum levels of the angiogenic factor pleiotrophin in relation
to disease stage in lung cancer patients. Br J Cancer. 86:858–863.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kadomatsu K and Muramatsu T: Midkine and
pleiotrophin in neural development and cancer. Cancer Lett.
204:127–143. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu YT, Shang D, Akatsuka S, Ohara H,
Dutta KK, Mizushima K, Naito Y, Yoshikawa T, Izumiya M, Abe K, et
al: Chronic oxidative stress causes amplification and
overexpression of ptprz1 protein tyrosine phosphatase to activate
beta-catenin pathway. Am J Pathol. 171:1978–1988. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tamura H, Fukada M, Fujikawa A and Noda M:
Protein tyrosine phosphatase receptor type Z is involved in
hippocampus-dependent memory formation through dephosphorylation at
Y1105 on p190 RhoGAP. Neurosci Lett. 399:33–38. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pariser H, Perez-Pinera P, Ezquerra L,
Herradon G and Deuel TF: Pleiotrophin stimulates tyrosine
phosphorylation of beta-adducin through inactivation of the
transmembrane receptor protein tyrosine phosphatase beta/zeta.
Biochem Biophys Res Commun. 335:232–239. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pariser H, Ezquerra L, Herradon G,
Perez-Pinera P and Deuel TF: Fyn is a downstream target of the
pleiotrophin/receptor protein tyrosine phosphatase
beta/zeta-signaling pathway: Regulation of tyrosine phosphorylation
of Fyn by pleiotrophin. Biochem Biophys Res Commun. 332:664–669.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rokavec M, Wu W and Luo JL: IL6-mediated
suppression of miR-200c directs constitutive activation of an
inflammatory signaling circuit that drives transformation and
tumorigenesis. Mol Cell. 45:777–789. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yang F and Li J: WHO classification of
tumors of the breast. Zhonghua Wai Ke Za Zhi. 52:1–3.
2014.PubMed/NCBI
|
|
18
|
Haffty BG, Yang Q, Reiss M, Kearney T,
Higgins SA, Weidhaas J, Harris L, Hait W and Toppmeyer D:
Locoregional relapse and distant metastasis in conservatively
managed triple negative early-stage breast cancer. J Clin Oncol.
24:5652–5657. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guarneri V, Dieci MV and Conte P: Relapsed
triple-negative breast cancer: Challenges and treatment strategies.
Drugs. 73:1257–1265. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Masuda H, Baggerly KA, Wang Y, Zhang Y,
Gonzalez-Angulo AM, Meric-Bernstam F, Valero V, Lehmann BD,
Pietenpol JA, Hortobagyi GN, et al: Differential response to
neoadjuvant chemotherapy among 7 triple-negative breast cancer
molecular subtypes. Clin Cancer Res. 19:5533–5540. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang V, Davis DA, Veeranna RP, Haque M and
Yarchoan R: Characterization of the activation of protein tyrosine
phosphatase, receptor-type, Z polypeptide 1 (PTPRZ1) by hypoxia
inducible factor-2 alpha. PLoS One. 5:e96412010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Meng K, Rodriguez-Peña A, Dimitrov T, Chen
W, Yamin M, Noda M and Deuel TF: Pleiotrophin signals increased
tyrosine phosphorylation of beta beta-catenin through inactivation
of the intrinsic catalytic activity of the receptor-type protein
tyrosine phosphatase beta/zeta. Proc Natl Acad Sci USA.
97:2603–2608. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ulbricht UI, Eckerich C, Fillbrandt R,
Westphal M and Lamszus K: RNA interference targeting protein
tyrosine phosphatase beta suppresses glioblastoma growth in vitro
and in vivo. J Neurochem. 98:1497–1506. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Foehr ED, Lorente G, Kuo J, Ram R,
Nikolich K and Urfer R: Targeting of the receptor protein tyrosine
phosphatase beta with a monoclonal antibody delays tumor growth in
a glioblastoma model. Cancer Res. 66:2271–2278. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Feng ZJ, Gao SB, Wu Y, Xu XF, Hua X and
Jin GH: Lung cancer cell migration is regulated via repressing
growth factor PTN/RPTP β/ζ signaling by menin. Oncogene.
29:5416–5426. 2010. View Article : Google Scholar : PubMed/NCBI
|
